Yoshiyuki Suzuki

Yoshiyuki Suzuki

Auto-generated profile, based on publicly available information

Yoshiyuki Suzuki

Department of Radiation Oncology, Fukushima Medical University School of Medicine, Fukushima, Japan

Research Focus & Metrics

Academic Career Length

12Years (2015-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
9 March 2015 in Journal of Radiation Research
Verified
Journal Article
Open access
PDF file
YYYuya Yoshimoto
Yuya Yoshimoto
TOTakahiro Oike
Takahiro Oike
NONoriyuki Okonogi
Noriyuki Okonogi
YSYoshiyuki Suzuki
Yoshiyuki Suzuki
KAKen Ando
Ken Ando
TNTakashi Nakano
Takashi Nakano
X-ray radiotherapy activates tumor antigen-specific T-cell responses, and increases in the serum levels of high mobility group box 1 (HMGB1) induced by X-ray irradiation play a pivotal role in activating anti-tumor immunity. Here, we examined whether carbon-ion beams, as well as X-rays, can induce HMGB1 release from human cancer cell lines. The study examined five human cancer cell lines: TE2, KYSE70, A549, NCI-H460 and WiDr. The proportion of cells surviving X- or carbon-ion beam irradiation was assessed in a clonogenic assay. The D 10 , the dose at which 10% of cells survive, was calculated using a linear–quadratic model. HMGB1 levels in the culture supernatants were assessed by an ELISA. The D 10 dose for X-rays in TE2, KYSE70, A549, NCI-H460 and WiDr cells was 2.1, 6.7, 8.0, 4.8 and 7.1 Gy, respectively, whereas that for carbon-ion beams was 0.9, 2.5, 2.7, 1.8 and 3.5 Gy, respectively. X-rays and carbon-ion beams significantly increased HMGB1 levels in the culture supernatants of A549, NCI-H460 and WiDr cells at 72 h post-irradiation with a D 10 dose. Furthermore, irradiation with X-rays or carbon-ion beams significantly increased HMGB1 levels in the culture supernatants of all five cell lines at 96 h post-irradiation. There was no significant difference in the amount of HMGB1 induced by X-rays and carbon-ion beams at any time-point (except at 96 h for NCI-H460 cells); thus we conclude that comparable levels of HMGB1 were detected after irradiation with iso-survival doses of X-rays and carbon-ion beams.

15 February 2017 in Clinical Case Reports
Verified
Journal Article
Open access
PDF file
HSHiro Sato
Hiro Sato
YSYoshiyuki Suzuki
Yoshiyuki Suzuki
YYYuya Yoshimoto
Yuya Yoshimoto
SNShin‐Ei Noda
Shin‐Ei Noda
KMKazutoshi Murata
Kazutoshi Murata
TNTakashi Nakano
Takashi Nakano
Key Clinical Message: The mechanism of abscopal effect is becoming clear by the progress of cancer immunology. A 54‐year‐old male with recurrent gastric cancer presented an abscopal effect after radiotherapy with concurrent adoptive T‐cell immunotherapy (immunoradiotherapy). Immunoradiotherapy has potential to induce abscopal effect by strengthening systemic antitumor immunity even in recurrent cancer.

1 January 2015 in FUKUSHIMA JOURNAL OF MEDICAL SCIENCE
Verified
Journal Article
Closed access
YYYuya Yoshimoto
Yuya Yoshimoto
KKKoji Kono
Koji Kono
YSYoshiyuki Suzuki
Yoshiyuki Suzuki
An anti-tumor immune response is one of the most important factors that can determine treatment response and prognosis of cancer patients. Recent studies have demonstrated that radiotherapy can activate tumor-specific immune responses and that these responses contribute to the therapeutic efficacy. However, the exact mechanisms underlying the radiation-induced immune responses remain unclear. Better understanding of the mechanisms could facilitate the application of immune-activating radiotherapy and provide new treatment strategies. We previously demonstrated that tumor-specific T cell responses could be induced in esophageal cancer patients during and after chemoradiotherapy. Furthermore, in a mouse model, immune responses played an important role in determining the local and systemic therapeutic efficacy of radiotherapy that could be augmented by the immune checkpoint blockade. In this review, radiotherapy-induced immune responses, the mechanisms underlying the induction of those responses, and a practical application of the therapy are discussed.

16 April 2015 in Journal of Radiation Research
Verified
Journal Article
Open access
PDF file
HUHiroki Ushijima
Hiroki Ushijima
YSYoshiyuki Suzuki
Yoshiyuki Suzuki
TOTakahiro Oike
Takahiro Oike
MKMayumi Komachi
Mayumi Komachi
YYYuya Yoshimoto
Yuya Yoshimoto
TNTakashi Nakano
Takashi Nakano
The mammalian target of rapamycin (mTOR) correlates with cell survival under hypoxia and regulates hypoxia-inducible factor-1α (HIF-1α), a key protein in hypoxia-related events. However, the role of mTOR in radio-resistance has not been fully investigated. Therefore, the effect of mTOR on the radio-resistance of cancer cells under hypoxia was evaluated using the mTOR inhibitor temsirolimus. Clonogenic survival was examined in the A549 human lung adenocarcinoma cell line under normoxia or hypoxia, with or without temsirolimus. An oxygen enhancement ratio (OER) was calculated using the D 10 values, the doses giving 10% survival. Western blotting was performed to investigate the effect of temsirolimus on mTOR and the HIF-1α pathway under normoxia and hypoxia. A549 cells showed a radio-resistance of 5.1 and 14.2 Gy, as indicated by D 10 values under normoxia and hypoxia, respectively; the OER was 2.8. The cell survival rates under hypoxia and with temsirolimus remarkably decreased compared with those under normoxia. The D 10 values of the cells under normoxia and hypoxia were 4.8 and 5.4 Gy, respectively (OER = 1.1). mTOR expression was suppressed by temsirolimus under both normoxia and hypoxia. HIF-1α expression decreased under hypoxia in the presence of temsirolimus. These results suggest that temsirolimus can overcome the radio-resistance induced by hypoxia. When the fact that mTOR acts upstream of HIF-1α is considered, our data suggest that the restoration of radiation sensitivity by temsirolimus under hypoxia may be associated with the suppression of the HIF-1α pathway. Temsirolimus could therefore be used as a hypoxic cell radio-sensitizer.

17 September 2018 in International Journal of Hyperthermia
Verified
Journal Article
Open access
KAKen Ando
Ken Ando
YSYoshiyuki Suzuki
Yoshiyuki Suzuki
TKTakuya Kaminuma
Takuya Kaminuma
YYYuya Yoshimoto
Yuya Yoshimoto
TOTakahiro Oike
Takahiro Oike
TNTakashi Nakano
Takashi Nakano
Purpose: This study aimed to elucidate the contribution of T cell-mediated antitumor immunity in the antitumor effect of local hyperthermia (LH). Materials and methods: C57BL/6J mice were injected with the mouse lymphoma cell line, E.G7-OVA, in the right femur on day 0. LH was induced by immersing the right femur in a water bath at 42 °C for 60 min on day 7, followed by administration of anti-CD8 monoclonal antibodies (mAb) or anti-CTLA-4 mAb (days 8, 11, and 14). The effect of LH on tumor growth (TG) was assessed by measuring the duration until tumor volume reached 1000 mm3 and survival time. Tumor-specific T cell responses were measured using enzyme-linked immunospot (ELISpot) assay. Results: TG with and without LH treatment was 9.0 ± 9.6 and 7.0 ± 1.6 days, respectively. TG was significantly slower with LH treatment (p = .01). The therapeutic effect of LH was mitigated by addition of anti-CD8 mAb (p < .05 for both TG and survival) compared with the untreated (control) group. Furthermore, addition of anti-CTLA-4 mAb did not significantly affect the therapeutic effect of LH. The ELISpot assay showed that the number of spots in the LH group (276.3 ± 14.5) was significantly greater than in the control group (59.0 ± 4.5, p < .001). Conclusion: CD8-positive T cell-mediated antitumor immunity significantly contributes to the antitumor effect of LH.

11 May 2023 in Cancer Reports
Verified
Journal Article
Open access
YTYuka Takehara
Yuka Takehara
KMKosaku Mimura
Kosaku Mimura
YSYoshiyuki Suzuki
Yoshiyuki Suzuki
YWYohei Watanabe
Yohei Watanabe
YYYuya Yoshimoto
Yuya Yoshimoto
KKKoji Kono
Koji Kono
Background: Several clinical trials of nivolumab have reported good results, including those in patients with advanced esophageal squamous cell carcinoma. However, the response rate of this drug remains poor. Notably, a rare phenomenon called abscopal effect refers to the regression of irradiated and nonirradiated distant tumors after local radiotherapy. Although the mechanism of this effect remains unclear, the antitumor immunity induced by radiotherapy is considered to be the most important factor.Case: A 66‐year‐old man with recurrent nivolumab‐resistant esophageal squamous cell carcinoma along with left‐side cervical and abdominal para‐aortic lymph node metastases was treated with a 40 Gy (10 fractions) dose of radiotherapy to the left‐side cervical lymph node metastasis as a palliative treatment, which caused neck pain. In addition, nivolumab administration was resumed the day after completion of radiotherapy. Three months after radiotherapy, the irradiated lesion on the left neck had regressed to a scar‐like lesion. Furthermore, the previously progressive abdominal para‐aortic lymph nodes outside the irradiation area shrank (abscopal effect). T‐cell receptor and B‐cell receptor (TCR/BCR) repertoire analyses before and after radiotherapy revealed that radiotherapy led to changes in the TCR/BCR repertoire.Conclusion: Changes in the TCR/BCR repertoire may be a part of the mechanism underlying the abscopal effect. The findings of the present case suggest that the combination of immune checkpoint inhibitors and radiotherapy is a promising treatment approach even for patients with immune checkpoint inhibitor‐resistant cancer.